Keros Therapeutics, Inc. announced on June 9, 2025, the conclusion of its previously announced review process to evaluate strategic alternatives. As a result, the company's Board of Directors unanimously determined to initiate a process to return $375 million of excess capital to stockholders.
The terms and structure of this capital return remain under consideration and are expected to be announced at a future date. This decision reflects a thorough review of capital requirements, feedback from stockholders, and confidence in the potential of Keros' lead product candidate, KER-065.
The Board, with the assistance of its strategic committee and advisors, evaluated a comprehensive range of alternatives, including a sale of the company, other business combinations, continued pipeline investment, and capital return. This move aims to enhance stockholder value while continuing to advance KER-065 for neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.